Shots:
- Roche has launched its Elecsys PRO-C3 test, developed with Nordic Bioscience to evaluate the severity of liver fibrosis in pts showing signs of metabolic dysfunction–associated steatotic liver disease
- Elecsys PRO-C3 test requires a single assay & in combination with ADAPT formula (incl. PRO-C3 levels, platelet count, age, & diabetes status) provides clear assessment of fibrosis severity, differentiating between significant fibrosis (≥F2), advanced fibrosis (≥F3), & cirrhosis (F4), with results delivered in 18min on Roche’s cobas analysers
- Also, ADAPT score will be calculated manually in start, with Roche planning to launch an automation software in late 2025 to further simplify liver fibrosis diagnosis
Ref: GlobeNewswire | Image: Roche
Related News:- Roche’s Chest Pain Triage Algorithm Secures European CE Mark to Detect Acute Coronary Syndrome (ACS)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click Here for Full Press Release
